Business Context and Reporting Period
Company: Oragenics, Inc. (OGEN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 27, 2025
Principal Event: Implementation of a One-for-Thirty (1-for-30) reverse stock split to comply with NYSE American continued listing standards.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split Ratio: The Board of Directors selected a 1-for-30 ratio, within the 1-for-5 to 1-for-50 range approved by shareholders on May 2, 2025.
- Effective Date: The split is anticipated to become effective at 12:01 a.m. Eastern Time on June 3, 2025.
- Share Count Adjustment: Based on 21,475,289 shares outstanding as of January 20, 2023, the post-split outstanding share count is projected to be approximately 715,843 shares.
- Authorized Capital: The authorized share count remains unchanged at 350,000,000 shares of Common Stock and 50,000,000 shares of Preferred Stock.
- Trading Symbol: The stock will continue to trade under the symbol "OGEN" on NYSE American but will utilize a new CUSIP Number (684023 609).
Outlook, Risks, and Management Commentary
- Reason for Action: The split is intended to expeditiously meet NYSE American listing standards and reduce the risk of delisting due to low trading prices.
- Fractional Shares: No fractional shares will be issued. Shareholders entitled to a fractional share will receive one whole share instead of cash consideration.
- Ownership Impact: Percentage ownership and voting power remain virtually unchanged, subject to minor rounding adjustments.
- Derivatives: Proportionate adjustments will be made to the exercise prices and share counts of outstanding stock options and warrants.
Investor Verification Checklist
- Verify the exact number of shares held in brokerage accounts post-split on June 3, 2025, noting the rounding up of fractional shares to whole shares.
- Confirm the new CUSIP Number (684023 609) for trading and settlement purposes.
- Review the impact on outstanding stock options and warrants, specifically the increased exercise price and reduced share count.
- Monitor the stock price performance post-split to ensure continued compliance with NYSE American listing standards.